A study published by researchers from the Papa Giovanni XXIII hospital in Italy has suggested that individuals previously infected with SARS-CoV-2 may benefit from a single dose of mRNA vaccine, rather than requiring the current 2-dose vaccine regimen.
The study published on a pre-print server included 184 healthcare workers who had previously suffered from a SARS-CoV-2 infection. They were evaluated both before and after receiving a second dosage of vaccine. Individuals who had not been infected by SARS-CoV-2 were evaluated both pre-and post-second vaccine doses.
The researchers found that individuals who had already been infected with SARS-CoV-2 were provided sufficient immunity by just a single shot. Individuals unaffected by the disease still received immunity after two doses, but this suggests that people with previous COVID-19 infection only require a single mRNA vaccine.
The researchers suggested that modifying the current global vaccine program to allow previously recovered individuals to just have a single dose of the vaccine would massively increase the speed of the vaccine rollout. This would also increase the number of vaccines available globally. Additionally, limiting the number of doses will limit the number of adverse events.
To know more about origin, virology of COVID-19, Click here
To know more about emerging themes in COVID-19, Click here
To know more about how WhiteCoats can help you in your professional advancement, visit www.whitecoats.com
Want to set up an online consultation for your practice, Click here